Ultrasound targeted microbubble destruction-mediated SOCS3 attenuates biological characteristics and epithelial-mesenchymal transition (EMT) of breast cancer stem cells

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–1150.
   PubMed Web of Science ®Google Scholar
• Anastasiadi Z, Lianos GD, Ignatiadou E, et al. Breast cancer in young women: an overview. Updates Surg. 2017;69:313–317.
   PubMed Web of Science ®Google Scholar
• Wormann B. Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm. 2017;40:55–64.
   PubMedGoogle Scholar
• Ganz PA, Goodwin PJ. Breast cancer survivorship: where are we today?. Adv Exp Med Biol. 2015;862:1–8.
   PubMed Web of Science ®Google Scholar
• Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13:1387–1397.
   PubMed Web of Science ®Google Scholar
• Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014;28:1101–7, 10.
   PubMed Web of Science ®Google Scholar
• Nassar D, Blanpain C. Cancer stem cells: basic concepts and therapeutic implications. Annu Rev Pathol. 2016;11:47–76.
   PubMed Web of Science ®Google Scholar
• Luo M, Clouthier SG, Deol Y, et al. Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol. 2015;1293:1–49.
   PubMedGoogle Scholar
• Bilek SL, Lay T. Variation of interplate fault zone properties with depth in the Japan subduction zone. Science (New York, NY). 1998;281:1175–1178.
   Google Scholar
• Zou Y, Chen Y, Yao S, et al. MiR-422a weakened breast cancer stem cells properties by targeting PLP2. Cancer Biol Ther. 2018;19:436–444.
   PubMed Web of Science ®Google Scholar
• Xie G, Ji A, Yuan Q, et al. Tumour-initiating capacity is independent of epithelial-mesenchymal transition status in breast cancer cell lines. Br J Cancer. 2014;110:2514–2523.
   PubMed Web of Science ®Google Scholar
• Liu S, Cong Y, Wang D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2014;2:78–91.
   PubMed Web of Science ®Google Scholar
• Sulaiman A, McGarry S, Han X, et al. CSCs in breast cancer-one size does not fit all: therapeutic advances in targeting heterogeneous epithelial and mesenchymal CSCs. Cancers (Basel). 2019;11:1128.
   PubMed Web of Science ®Google Scholar
• Dittmer J. Breast cancer stem cells: features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59–74.
   PubMed Web of Science ®Google Scholar
• Groner B, von Manstein V. Jak stat signaling and cancer: opportunities, benefits and side effects of targeted inhibition. Mol Cell Endocrinol. 2017;451:1–14.
   PubMed Web of Science ®Google Scholar
• Inan S, Hayran M. Cell signaling pathways related to epithelial mesenchymal transition in cancer metastasis. Crit Rev Oncog. 2019;24:47–54.
   PubMedGoogle Scholar
• Slattery ML, Lundgreen A, Kadlubar SA, et al. JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog. 2013;52:155–166.
   PubMed Web of Science ®Google Scholar
• Liu K, Wu Z, Chu J, et al. Promoter methylation and expression of SOCS3 affect the clinical outcome of pediatric acute lymphoblastic leukemia by JAK/STAT pathway. Biomed Pharmacother. 2019;115:108913.
   PubMed Web of Science ®Google Scholar
• Li Y, Hodge J, Liu Q, et al. TFEB is a master regulator of tumor-associated macrophages in breast cancer. J Immunother Cancer. 2020;8:e000543.
   PubMed Web of Science ®Google Scholar
• Xu JZ, Shao CC, Wang XJ, et al. circTADA2As suppress breast cancer progression and metastasis via targeting miR-203a-3p/SOCS3 axis. Cell Death Dis. 2019;10:175.
   PubMed Web of Science ®Google Scholar
• Jiang M, Zhang W, Zhang R, et al. Cancer exosome-derived miR-9 and miR-181a promote the development of early-stage MDSCs via interfering with SOCS3 and PIAS3 respectively in breast cancer. Oncogene. 2020;39:4681–4694.
   PubMed Web of Science ®Google Scholar
• Zhang KJ, Tan XL, Guo L. The long non-coding RNA DANCR regulates the inflammatory phenotype of breast cancer cells and promotes breast cancer progression via EZH2-dependent suppression of SOCS3 transcription. Mol Oncol. 2020;14:309–328.
   PubMed Web of Science ®Google Scholar
• Muhammad N, Bhattacharya S, Steele R, et al. Anti-miR-203 suppresses ER-positive breast cancer growth and stemness by targeting SOCS3. Oncotarget. 2016;7:58595–58605.
   PubMedGoogle Scholar
• Thiagarajan PS, Zheng Q, Bhagrath M, et al. STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance. Endocr Relat Cancer. 2017;24:415–426.
   PubMed Web of Science ®Google Scholar
• Sun W, Shi Q, Zhang H, et al. Advances in the techniques and methodologies of cancer gene therapy. Discov Med. 2019;27:45–55.
   PubMed Web of Science ®Google Scholar
• Wu J, Li RK. Ultrasound-targeted microbubble destruction in gene therapy: a new tool to cure human diseases. Genes Dis. 2017;4:64–74.
   PubMed Web of Science ®Google Scholar
• Liu YM, Li XF, Liu H, et al. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells. Oncol Rep. 2015;34:2977–2986.
   PubMed Web of Science ®Google Scholar
• Chen H, Hwang JH. Ultrasound-targeted microbubble destruction for chemotherapeutic drug delivery to solid tumors. J Ther Ultrasound. 2013;1:10.
   PubMedGoogle Scholar
• Tinkov S, Bekeredjian R, Winter G, et al. Microbubbles as ultrasound triggered drug carriers. J Pharm Sci. 2009;98:1935–1961.
   PubMed Web of Science ®Google Scholar
• Tu J, Zhang H, Yu J, et al. Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy. Onco Targets Ther. 2018;11:5763–5775.
   PubMed Web of Science ®Google Scholar
• Tang W, Li M, Qi X, et al. β1,4-Galactosyltransferase V modulates breast cancer stem cells through Wnt/β-catenin signaling pathway. Cancer Res Treat. 2020;52:1084–1102.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Y, Li Z, et al. Ultrasound-Targeted Microbubble Destruction (UTMD) combined with liposome increases the effectiveness of suppressing proliferation, migration, invasion, and Epithelial- Mesenchymal Transition (EMT) via Targeting Metadherin (MTDH) by ShRNA. Med Sci Monit. 2019;25:2640–2648.
   PubMed Web of Science ®Google Scholar
• Zhang W, Jiang M, Chen J, et al. SOCS3 Suppression Promoted the Recruitment of CD11b(+)Gr-1(-)F4/80(-)MHCII(-) early-stage myeloid-derived suppressor cells and accelerated Interleukin-6-Related tumor invasion via affecting myeloid differentiation in breast cancer. Front Immunol. 2018;9:1699.
   PubMed Web of Science ®Google Scholar
• Shi D, Guo L, Sun X, et al. UTMD inhibit EMT of breast cancer through the ROS/miR-200c/ZEB1 axis. Sci Rep. 2020;10:6657.
   PubMedGoogle Scholar
• Ji Y, Han Z, Shao L, et al. Ultrasound-targeted microbubble destruction of calcium channel subunit alpha 1D siRNA inhibits breast cancer via G protein-coupled receptor 30. Oncol Rep. 2016;36:1886–1892.
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–3988.
   PubMed Web of Science ®Google Scholar
• Chen S, Grayburn PA. Ultrasound-targeted microbubble destruction for cardiac gene delivery. Methods Mol Biol. 2017;1521:205–218.
   PubMedGoogle Scholar
• Geis NA, Katus HA, Bekeredjian R. Microbubbles as a vehicle for gene and drug delivery: current clinical implications and future perspectives. Curr Pharm Des. 2012;18:2166–2183.
   PubMed Web of Science ®Google Scholar
• Liao Y, Luo H, He Z, et al. A combination of UTMD-Mediated HIF-1alpha shRNA transfection and TAE in the treatment of hepatic cancer. Biomed Res Int. 2019;2019:1937460.
   PubMed Web of Science ®Google Scholar
• Zhao R, Liang X, Zhao B, et al. Ultrasound assisted gene and photodynamic synergistic therapy with multifunctional FOXA1-siRNA loaded porphyrin microbubbles for enhancing therapeutic efficacy for breast cancer. Biomaterials. 2018;173:58–70.
   PubMed Web of Science ®Google Scholar
• Pedroso JAB, Ramos-Lobo AM, Donato J Jr. SOCS3 as a future target to treat metabolic disorders. Hormones (Athens). 2019;18:127–136.
   PubMedGoogle Scholar
• Speth JM, Penke LR, Bazzill JD, et al. Alveolar macrophage secretion of vesicular SOCS3 represents a platform for lung cancer therapeutics. JCI Insight. 2019;4. DOI:10.1172/jci.insight.131340.
   PubMed Web of Science ®Google Scholar
• Wang J, Guo J, Fan H. MiR-155 regulates the proliferation and apoptosis of pancreatic cancer cells through targeting SOCS3. Eur Rev Med Pharmacol Sci. 2019;23:5168–5175.
   PubMed Web of Science ®Google Scholar
• Gao Y, Zhao H, Wang P, et al. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases. Scand J Immunol. 2018;88:e12727.
   PubMed Web of Science ®Google Scholar
• Sun D, Jiang Z, Chen Y, et al. MiR-455-5p upregulation in umbilical cord mesenchymal stem cells attenuates endometrial injury and promotes repair of damaged endometrium via Janus kinase/signal transducer and activator of transcription 3 signaling. Bioengineered. 2021;2:78–91.
   Google Scholar
• Li MZ, Lai DH, Zhao HB, et al. SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells. Eur Rev Med Pharmacol Sci. 2017;21:3005–3011.
   PubMed Web of Science ®Google Scholar
• Subramani R, Nandy SB, Pedroza DA, et al. Role of growth hormone in breast cancer. Endocrinology. 2017;158:1543–1555.
   PubMed Web of Science ®Google Scholar
• Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol. 2014;5:58.
   PubMed Web of Science ®Google Scholar
• Liu Z, Gan L, Zhou Z, et al. SOCS3 promotes inflammation and apoptosis via inhibiting JAK2/STAT3 signaling pathway in 3T3-L1 adipocyte. Immunobiology. 2015;220:947–953.
   PubMed Web of Science ®Google Scholar
• Barclay JL, Anderson ST, Waters MJ, et al. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer. 2009;124:1756–1766.
   PubMedGoogle Scholar
• Fu Y, Kaneko K, Lin HY, et al. Gut hormone GIP induces inflammation and insulin resistance in the hypothalamus. Endocrinology. 2020;46:161.
   PubMedGoogle Scholar